ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 438

Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?

Marilyn Wan1, Jessica Walsh 2, M. Elaine Husni 3, Jose Scher 4, Soumya Reddy 5 and Alexis Ogdie 6, 1University of Pennsylvania, Philadelphia, 2Division of Rheumatology, University of Utah, Salt Lake City, UT, 3Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 4Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, 5Division of Rheumatology, New York University School of Medicine, New York, NY, 6Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Health Assessment Questionnaire and health outcome, patient outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The multi-dimensional health assessment questionnaire (MDHAQ) is a patient-reported outcome that is commonly used in clinical practice in the US and comprises of 10 items. Although the validated Health Assessment Questionnaire Disability Index (HAQDI) measures similar constructs as the MDHAQ, is less commonly used and has 16 items. Therefore, the objective of this study is to assess if the MDHAQ (divided by 3.33 to transform to the same scale as HAQDI) can substitute for the HAQDI in ACR20 assessment and cohort studies.

Methods: Between 2016-2019, patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC), a longitudinal observational cohort at four United States institutions: University of Pennsylvania, Cleveland Clinic, New York University, and University of Utah.  Baseline patient characteristics were descriptively reported. A priori we hypothesized that the MDHAQ and HAQDI would have high correlation at baseline ( >0.8) and among the change scores ( >0.8) and that responsiveness would be similar. Correlations were calculated among the total scores using Spearman’s correlation coefficients at baseline and follow-up visit. Change scores (e.g., score at visit 1 minus score at visit 2) and standardized mean responses were calculated. Sensitivity analyses excluding patients with low disease activity were calculated. We additionally examined agreement with the 20% improvement cut-off to determine the potential effect of using MDHAQ in the ACR20 criteria in place of HAQDI.

Results: HAQDI and MDHAQ data were available in 438 visits in which both questionnaires were completed and 161 patients with HAQDI and MDHAQ at two time points.  The mean age was 51.5 ± 14.6 years old, 53% were male, and most had low disease activity with mean swollen (66) and tender (68) joint counts 2.3 ± 4.4 and 4.3 ± 6.4, respectively. At baseline, the mean HAQDI was 0.64 ± 0.62 (range 0-3) and the mean MDHAQ was 1.9 ± 1.7 (range 0-10; Table 1). Dividing the MDHAQ by 3.33 to transform it to the same scale as the HAQDI resulted in a transformed MDHAQ mean of 0.56 ± 0.48 with a mean excursion from the HAQDI score of 0.07 ± 0.35 (Figure 1).  Among all time points, the Spearman’s correlation coefficient between the two instruments was 0.84 and among the first visit only, the coefficient was 0.83. The mean change over two visits in the HAQDI was -0.07 ± 0.4, with a standardized response mean (SRM) of 0.19 and mean change in the MDHAQ was -0.16 ± 1.1 with an SRM of 0.14. The Spearman’s correlation coefficient among the two change variables was 0.55 (Table 2). Using the 20% criteria for the ACR20, the agreement among use of HAQ-DI and MDHAQ is 74%. When excluding patients with a clinical Disease Activity index for Psoriatic Arthritis (c-DAPSA) score < 14 (i.e., low disease activity), the correlation coefficients were similar.

Conclusion: Although the HAQDI consists of more questions than the MDHAQ, the total scores correlated well when analyzed cross-sectionally. However, the correlation was moderate between the change over time. Using the 20% improvement cut-off, most were correctly classified with MDHAQ but MDHAQ cannot directly replace HAQDI for the ACR20 criteria.

Acknowledgement: Funded by NIH/NIAMS R01 AR072363


Table 1

Table 1. Baseline characteristics of patient cohort -n=278-


Table 2

Table 2. Correlation among HAQDI and MDHAQ and Responsiveness to change

Figure 1. Distribution of change in HAQDI vs change in MDHAQ/3.33


Disclosure: M. Wan, None; J. Walsh, AbbVie, 2, 5, ABBVIE, NOVARTIS, LILLY, AMGEN, UCB, 5, Amgen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, PFIZER, ABBVIE, 2, UCB, 5; M. Husni, Abbvie, 5, AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB, 5, Abbvie, Amgen, Janssen, Novartis, Lilly, Regeneron, Pfizer and UCB, 5, Bristol-Myers Squibb, 5, Eli Lilly, 5, Genentech, 5, Janssen, 5, Janssen Research & Development, LLC, 2, 3, Novartis, 5, PASE questionnaires, 7, Pfizer, 5, Sanofi-Genzyme, 5, UCB, 5; J. Scher, Amgen, 5, Bristol-Myers Squibb, 5, Janssen, 5, Novartis, 2, 5, Pfizer, 2, UCB, 5; S. Reddy, Novartis, 5, Pfizer, 8, UCB, Amgen, 5, Abbvie, 5; A. Ogdie, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda, 5, Amgen, 2, 4, 5, 8, Amgen to Forward National Databank, 2, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 4, 5, 8, Corrona, 5, CORRONA, 5, From Noavrtis to husband, 7, Lilly, 5, Lily, 5, Novartis, 2, 5, 7, Novartis to UPenn, 2, Novartis, Pfizer, 2, Pfizer, 2, 5, Pfizer Inc, 2, 5, Pfizer to UPenn, 2.

To cite this abstract in AMA style:

Wan M, Walsh J, Husni M, Scher J, Reddy S, Ogdie A. Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/longitudinal-construct-validity-and-responsiveness-of-mdhaq-and-haqdi-in-psa-can-mdhaq-replace-haqdi/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-construct-validity-and-responsiveness-of-mdhaq-and-haqdi-in-psa-can-mdhaq-replace-haqdi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology